NO20000230L - Treatment of diabetes with thiazolidinedione, insulin secretagogue and <alfa> glucosidase inhibitor - Google Patents

Treatment of diabetes with thiazolidinedione, insulin secretagogue and <alfa> glucosidase inhibitor

Info

Publication number
NO20000230L
NO20000230L NO20000230A NO20000230A NO20000230L NO 20000230 L NO20000230 L NO 20000230L NO 20000230 A NO20000230 A NO 20000230A NO 20000230 A NO20000230 A NO 20000230A NO 20000230 L NO20000230 L NO 20000230L
Authority
NO
Norway
Prior art keywords
glucosidase inhibitor
thiazolidinedione
alfa
diabetes
treatment
Prior art date
Application number
NO20000230A
Other languages
Norwegian (no)
Other versions
NO20000230D0 (en
Inventor
Robin Edwin Buckingham
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20000230L publication Critical patent/NO20000230L/en
Publication of NO20000230D0 publication Critical patent/NO20000230D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Fremgangsmåte for behandling av diabetes mellitus og tilstander knyttet til diabetes mellitus hos et pattedyr, der fremgangsmåten omfatter tilførsel av en effektiv, ikke-toksisk og farmasøytisk akseptabel mengde av en insulinsensitiserende forbindelse, en insulinsekretagogue og en alfa-glukosidaseinhibitor antihyperglykemisk forbindelse, til et pattedyr som har behov for dette, og blanding til bruk i en slik fremgangsmåte.A method of treating diabetes mellitus and conditions related to diabetes mellitus in a mammal, the method comprising administering an effective, non-toxic and pharmaceutically acceptable amount of an insulin sensitizing compound, an insulin secretagogue and an alpha-glucosidase inhibitor antihyperglycemic compound, need this, and blend for use in such a process.

NO20000230A 1997-07-18 2000-01-17 Treatment of diabetes with thiazolidinedione, insulin secretagogue and <alfa> glucosidase inhibitor NO20000230D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment
PCT/GB1998/002112 WO1999003478A1 (en) 1997-07-18 1998-07-16 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor

Publications (2)

Publication Number Publication Date
NO20000230L true NO20000230L (en) 2000-01-17
NO20000230D0 NO20000230D0 (en) 2000-01-17

Family

ID=10816170

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000230A NO20000230D0 (en) 1997-07-18 2000-01-17 Treatment of diabetes with thiazolidinedione, insulin secretagogue and <alfa> glucosidase inhibitor

Country Status (27)

Country Link
EP (1) EP1001784A1 (en)
JP (1) JP2001510160A (en)
KR (1) KR20010021952A (en)
CN (1) CN1263467A (en)
AP (1) AP2000001735A0 (en)
AR (2) AR016350A1 (en)
AU (1) AU8449098A (en)
BG (1) BG104062A (en)
BR (1) BR9810292A (en)
CA (1) CA2297133A1 (en)
CO (1) CO4940489A1 (en)
DZ (1) DZ2563A1 (en)
EA (1) EA200000140A1 (en)
GB (1) GB9715298D0 (en)
HU (1) HUP0003626A3 (en)
ID (1) ID23804A (en)
IL (1) IL133907A0 (en)
MA (1) MA24608A1 (en)
NO (1) NO20000230D0 (en)
OA (1) OA11312A (en)
PE (1) PE99499A1 (en)
PL (1) PL338140A1 (en)
SK (1) SK612000A3 (en)
TR (1) TR200000133T2 (en)
UY (1) UY25101A1 (en)
WO (1) WO1999003478A1 (en)
ZA (1) ZA986364B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ATE372782T1 (en) 1999-06-21 2007-09-15 Lilly Co Eli SYNERGITIC USE OF THIAZOLIDINEDIONES AND GLUCAGONE-LIKE PEPTIDE-1 AND THEIR AGONISTS FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES
JP2003520226A (en) * 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト Combination comprising a dipeptidyl peptidase-IV inhibitor and an antidiabetic agent
WO2001062295A1 (en) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Drugs containing combined active ingredients
JP4917712B2 (en) * 2000-02-24 2012-04-18 武田薬品工業株式会社 Concomitant medication
EP1738751B1 (en) 2001-01-12 2011-05-11 Sun Pharma Advanced Research Company Ltd Spaced drug delivery system
FR2832930A1 (en) * 2001-12-03 2003-06-06 Lipha PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES
CA2540225C (en) 2003-10-31 2012-03-06 Takeda Pharmaceutical Company Limited Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
CN101103993B (en) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 Hypoglycemic medicine composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2101866T3 (en) * 1991-08-26 1997-07-16 Upjohn Co LIQUID FOOD PRODUCT CONTAINING 3-GUANIDINOPROPIONIC ACID.
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
EA200000140A1 (en) 2000-06-26
CN1263467A (en) 2000-08-16
TR200000133T2 (en) 2000-09-21
SK612000A3 (en) 2000-07-11
IL133907A0 (en) 2001-04-30
JP2001510160A (en) 2001-07-31
AP2000001735A0 (en) 2000-01-16
DZ2563A1 (en) 2003-02-15
UY25101A1 (en) 2000-12-29
KR20010021952A (en) 2001-03-15
ZA986364B (en) 2000-01-17
CO4940489A1 (en) 2000-07-24
WO1999003478A1 (en) 1999-01-28
CA2297133A1 (en) 1999-01-28
EP1001784A1 (en) 2000-05-24
NO20000230D0 (en) 2000-01-17
HUP0003626A2 (en) 2001-05-28
AR019724A2 (en) 2002-03-13
PL338140A1 (en) 2000-09-25
PE99499A1 (en) 1999-12-18
AU8449098A (en) 1999-02-10
BG104062A (en) 2000-11-30
MA24608A1 (en) 1999-04-01
BR9810292A (en) 2000-09-19
ID23804A (en) 2000-05-11
HUP0003626A3 (en) 2001-12-28
AR016350A1 (en) 2001-07-04
GB9715298D0 (en) 1997-09-24
OA11312A (en) 2003-10-24

Similar Documents

Publication Publication Date Title
NO20090846L (en) Combination and pharmaceutical composition for the treatment of diabetes and its use
EA200300036A1 (en) COMBINATION OF DIPEPTIDYLPEPIDIDASE INHIBITORS IV AND OTHER ANTI-DIABETIC AGENTS FOR THE TREATMENT OF DIABETES MELLITUS
NO970519L (en) Treatment of type II diabetes mellitus with amylin agonists
NO20083276L (en) Treatment of diabetes with thiazolidinedione and sulfonylurea
BR0308904A (en) Method of treatment of gastroparesis and use of a glp-1 compound
NO20000230L (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and &lt;alfa&gt; glucosidase inhibitor
SE9803760D0 (en) Methods to treat and diagnose the restless legs syndrome and the corresponding agents
WO2001091774A3 (en) Method of treating chronic ulcers
CA2296653A1 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
NO996270L (en) Treatment of diabetes with thiazolidinedione and &lt;alfa&gt; glucosidase inhibitor
HUP0003260A2 (en) Pharmaceutical composition for treatment of diabetes with rosiglitazone and insulin
HUP0104388A2 (en) Combinations comprising a betha-agonist and a further antidiabetic agent
EA200000141A1 (en) METHOD OF TREATMENT OF DIABETAS BY THIAZOLIDINDIONE AND SULFONYL URIDE
WO2001047509A3 (en) Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
EA199800177A1 (en) A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
CO5150158A1 (en) NEW ANTIDIABETIC TREATMENT
TR200000957T2 (en) The use of thiazolidinedione in the treatment of hyperglycemia
HUP0002569A2 (en) Pharmaceutical compositions for treatment of diabetes containing thiazolidinedione and alpha-glucosidase inhibitors
ECSP982593A (en) NEW METHOD OF TREATMENT VI
ECSP982534A (en) NEW METHOD OF TREATMENT
ECSP993146A (en) TREATMENT METHOD FOR DIABETES USING AN AP2 INHIBITOR AND ITS COMBINATION

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application